Journal Article
L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Wu, M., Barbara-Burnham, L., and Young, L. S.,
“Activities of bay Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice.”,
Antimicrobial agents and chemotherapy, vol. 40, no. 3, pp. 546-51, 1996.
C. B. Inderlied, Barbara-Burnham, L., Wu, M., Young, L. S., and Bermudez, L. E.,
“Activities of the benzoxazinorifamycin KRM 1648 and ethambutol against Mycobacterium avium complex in vitro and in macrophages.”,
Antimicrobial agents and chemotherapy, vol. 38, no. 8, pp. 1838-43, 1994.
L. E. Bermudez, Kolonoski, P., Young, L. S., and Inderlied, C. B.,
“Activity of KRM 1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection.”,
Antimicrobial agents and chemotherapy, vol. 38, no. 8, pp. 1844-8, 1994.
L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Petrofsky, M., Aralar, P., Wu, M., and Young, L. S.,
“Activity of moxifloxacin by itself and in combination with ethambutol, rifabutin, and azithromycin in vitro and in vivo against Mycobacterium avium.”,
Antimicrobial agents and chemotherapy, vol. 45, no. 1, pp. 217-22, 2001.
L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Petrofsky, M., and Young, L. S.,
“Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige mice.”,
Antimicrobial agents and chemotherapy, vol. 38, no. 12, pp. 2717-21, 1994.
L. E. Bermudez, Nash, K., Petrofsky, M., Young, L. S., and Inderlied, C. B.,
“Clarithromycin-resistant mycobacterium avium is still susceptible to treatment with clarithromycin and is virulent in mice.”,
Antimicrobial agents and chemotherapy, vol. 44, no. 10, pp. 2619-22, 2000.
L. E. Bermudez, Nash, K. A., Petrofsky, M., Young, L. S., and Inderlied, C. B.,
“Effect of ethambutol on emergence of clarithromycin-resistant Mycobacterium avium complex in the beige mouse model.”,
The Journal of infectious diseases, vol. 174, no. 6, pp. 1218-22, 1996.
L. E. Bermudez and Inderlied, C. B.,
“Effect of Mycobacterium avium infection on the influx, accumulation, and efflux of KRM-1648 by human macrophages.”,
Microbial drug resistance (Larchmont, N.Y.), vol. 3, no. 3, pp. 277-82, 1997.
L. E. Bermudez, Petrofsky, M., Inderlied, C. B., and Young, L. S.,
“Efficacy of azithromycin and rifabutin in preventing infection by Mycobacterium avium complex in beige mice.”,
The Journal of antimicrobial chemotherapy, vol. 36, no. 4, pp. 641-6, 1995.
L. E. Bermudez, Wu, M., Miltner, E., and Inderlied, C. B.,
“Isolation of two subpopulations of Mycobacterium avium within human macrophages.”,
FEMS microbiology letters, vol. 178, no. 1, pp. 19-26, 1999.
L. E. Bermudez, Kolonoski, P., Wu, M., Aralar, P. A., Inderlied, C. B., and Young, L. S.,
“Mefloquine is active in vitro and in vivo against Mycobacterium avium complex.”,
Antimicrobial agents and chemotherapy, vol. 43, no. 8, pp. 1870-4, 1999.
L. S. Young, Bermudez, L. E., and Inderlied, C. B.,
“Mycobacteria and AIDS: treatment, prevention and future prospects.”,
Research in microbiology, vol. 143, no. 4, pp. 420-2, 1992.
C. B. Inderlied, Kemper, C. A., and Bermudez, L. E.,
“The Mycobacterium avium complex.”,
Clinical microbiology reviews, vol. 6, no. 3, pp. 266-310, 1993.
L. E. Bermudez, Inderlied, C. B., and Young, L. S.,
“Mycobacterium avium complex in AIDS.”,
Current clinical topics in infectious diseases, vol. 12, pp. 257-81, 1992.
L. E. Bermudez, Wu, M., Young, L. S., and Inderlied, C. B.,
“Postantibiotic effect of amikacin and rifapentine against Mycobacterium avium complex.”,
The Journal of infectious diseases, vol. 166, no. 4, pp. 923-6, 1992.
L. S. Young, Bermudez, L. E., and Inderlied, C. B.,
“Practical issues in the antibiotic and immunotherapy of Mycobacterium avium disease in immunocompromised patients.”,
Research in microbiology, vol. 145, no. 3, pp. 206-9, 1994.
L. E. Bermudez, Young, L. S., and Inderlied, C. B.,
“Rifabutin and sparfloxacin but not azithromycin inhibit binding of Mycobacterium avium complex to HT-29 intestinal mucosal cells.”,
Antimicrobial agents and chemotherapy, vol. 38, no. 5, pp. 1200-2, 1994.
L. E. Bermudez, Inderlied, C. B., Kolonoski, P., Wu, M., Aralar, P., and Young, L. S.,
“Telithromycin is active against Mycobacterium avium in mice despite lacking significant activity in standard in vitro and macrophage assays and is associated with low frequency of resistance during treatment.”,
Antimicrobial agents and chemotherapy, vol. 45, no. 8, pp. 2210-4, 2001.